Results 1 to 10 of about 26,226 (199)

Fondaparinux

Italian Journal of Medicine, 2013
AIM OF THE STUDY To review the best evidence-based knowledge about the clinical pharmacology and use of fondaparinux. DESIGN OF THE STUDY Narrative review. RESULTS Fondaparinux is a synthetic pentasaccharide anticoagulant that binds selectively with high
G. Airoldi, M. Campanini
doaj   +5 more sources

Fondaparinux monitoring in a patient with heparin-induced thrombocytopenia on hemodialysis [PDF]

Srpski Arhiv za Celokupno Lekarstvo, 2016
Introduction. Heparin-induced thrombocytopenia associated to hemodialysis is rare. In case when citrate dialysis and/or non-heparin anticoagulants are not available, only possible medication to use for anticoagulation during hemodialysis is ...
Kušić Jovana, Kulić Andrijana, Đurković Veselinka, Marković Rodoljub, Milačić Velja, Surić-Lambić Ljiljana, Peković Gordana   +6 more
doaj   +2 more sources

Associação entre o Uso de Fondaparinux com Acesso Radial e Desfechos Clínicos em Pacientes com Síndrome Coronariana Aguda sem Supradesnivelamento do Segmento ST [PDF]

Arquivos Brasileiros de Cardiologia
Resumo Fundamento: Tanto o fondaparinux quanto o acesso radial têm sido associados a menores taxas de eventos adversos cardiovasculares maiores (MACE) em pacientes com síndrome coronariana aguda (SCA).
Luiz Eduardo Fonteles Ritt, Eduardo Sahade Darze, Pedro Gabriel Melo de Barros e Silva, Gilson Soares Feitosa-Filho, João Victor Santos Pereira Ramos, Márcia A. Viana, Priscila Neri Lacerda, Emanoela Lima Freitas, Queila Oliveira Borges, Adriano Oliveira Martins, Renato Delascio Lopes   +10 more
doaj   +2 more sources

Fondaparinux Sodium: Recent Advances in the Management of Thrombosis

Journal of Cardiovascular Pharmacology and Therapeutics, 2023
Fondaparinux sodium is a chemically synthesized selective factor Xa inhibitor approved for the prevention and treatment of venous thromboembolic events, that is, deep vein thrombosis, pulmonary embolism, and superficial vein thrombosis, in acutely ill ...
Rupert M. Bauersachs MD
doaj   +2 more sources

Fondaparinux Pre-, Peri-, And/Or Postpartum for the Prophylaxis/Treatment of Venous Thromboembolism (FondaPPP)

Clinical and Applied Thrombosis/Hemostasis, 2021
We analyzed data for women who received fondaparinux for ≥7 days during pregnancy. The study retrospectively included women who received fondaparinux pre-, peri- and/or postpartum for ≥7 days for prophylaxis/venous thromboembolism (VTE) treatment at ...
Juergen Koscielny, Peter Bramlage, Birgit Linnemann   +2 more
exaly   +2 more sources

Rivaroxaban versus low-molecular-weight heparin and fondaparinux for preventing deep vein thrombosis after total knee arthroplasty in high-altitude residents: a randomized controlled trial [PDF]

Trials
Background High-altitude residence (defined as ≥ 1500 m above sea level) is associated with chronic hypoxia and increased thrombotic risk. This study aimed to evaluate the comparative efficacy and safety of rivaroxaban, low-molecular-weight heparin (LMWH)
Liangjuan Ren, Hongxia Fang, Xiaoqin Fu, Xin Chu, Xinjun Liu, Lihan Shi, Pai Zheng   +6 more
doaj   +2 more sources

Fondaparinux versus argatroban for the management of suspected or confirmed heparin-induced thrombocytopenia: a propensity score–matched cohort study [PDF]

Frontiers in Medicine
BackgroundHeparin-induced thrombocytopenia (HIT) is a prothrombotic, immune-mediated adverse drug reaction associated with significant morbidity and mortality.
Lama Alfehaid, Lama Alfehaid, Lama Alfehaid, Khalid Al Sulaiman, Khalid Al Sulaiman, Khalid Al Sulaiman, Khalid Al Sulaiman, Khalid Al Sulaiman, Abdulmajeed M. Alshehri, Abdulmajeed M. Alshehri, Abdulmajeed M. Alshehri, Saleh Alyousef, Sarah Alotaibi, Weam Abualghaith, Raghad Alsabr, Ramesh Vishwakarma, Nada Alsuhebany, Nada Alsuhebany, Nada Alsuhebany, Abdulrahman I. Alshaya, Abdulrahman I. Alshaya, Abdulrahman I. Alshaya, Shmeylan Al Harbi, Shmeylan Al Harbi, Shmeylan Al Harbi   +24 more
doaj   +2 more sources

Use of fondaparinux in patients with heparin-induced thrombocytopenia on veno-venous extracorporeal membrane oxygenation: A three-patient case series report

Frontiers in Medicine, 2023
Heparin-induced thrombocytopenia is a life-threatening immune-mediated complication of unfractionated heparin therapy. Fondaparinux is a therapeutic alternative, but it has limited evidence for its use in patients on extracorporeal membrane oxygenation ...
Jitka Rychlíčková, Jitka Rychlíčková, Jitka Rychlíčková, Vladimír Šrámek, Vladimír Šrámek, Pavel Suk, Pavel Suk   +6 more
doaj   +1 more source

Study on the safety and effectiveness of low-dose vs. regular-dose fondaparinux in preventing venous thromboembolism prophylaxis following total knee arthroplasty

Frontiers in Cardiovascular Medicine, 2023
BackgroundThis study aims to evaluate the effectiveness and safety of low-dose (1.5 mg) fondaparinux for venous thromboembolism (VTE) prophylaxis in patients post-total knee arthroplasty (TKA).MethodsWe retrospectively identified 314 patients who carried
Ping-bo Chen, Jing Wang, Lei Wang, Shou-liang Xiong, Chao Wang, Xin Yang, Cong-ming Li, Qiang Wang, Yin-chang Zhang   +8 more
doaj   +1 more source

Fondaparinux cross-reactivity in heparin-induced thrombocytopenia successfully treated with high-dose intravenous immunoglobulin and rivaroxaban

Platelets, 2020
HIT, a prothrombotic disorder caused by heparin-dependent antibodies, is often treated with fondaparinux, usually with good outcomes. A 70-year-old female developed severe HIT (platelet count, 25 × 109/L) post-glioblastoma resection during heparin ...
Farheen Manji, Theodore E. Warkentin, Jo-Ann I. Sheppard, Adrienne Lee   +3 more
doaj   +1 more source